Article Information
History
- April 11, 2022.
Article Versions
- Version 1 (April 14, 2020 - 06:36).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Chuanxi Fua,#,*,
- Zheng weia,#,
- Fengchang Zhub,#,
- Sen Peic,
- Shunping Lid,e,
- Liuren Zhanga,
- Xiaohui Suna,
- Yue Wua,
- Ping Liud,e and
- Mark Jitf
- aInstitute of Infectious Disease and Vaccine, School of Public Health, Zhejiang Chinese Medical University, Hangzhou, China
- bChinese Pharmaceutical Association, Beijing, China
- cMailman School of Public Health, Columbia University, New York, USA
- dSchool of Health Care Management, Shandong University, Jinan, China
- eNHC Key Laboratory of Health Economics and Policy Research, Shandong University, Jinan, China
- fDepartment of Infectious Disease Epidemiology, London School of Hygiene & Tropical Medicine, London, UK
- ↵*Corresponding author: Chuanxi Fu, PhD, Institute of Infectious Disease and Vaccine, Zhejiang Chinese Medical University, No.548, Binwen Rd, Hangzhou, 310053, China. E-mail: fuchuanxi{at}gmail.com
↵# These authors contributed equally to this work.